SymBio Pharmaceuticals Limited revised earnings guidance for the fiscal year ending December 31, 2023. For the period, the company revised net sales to JPY 5,589 million from JPY 5,603 million, operating loss to JPY 811 million from JPY 680 million, loss attributable to owners of parent to JPY 1,962 million from JPY 1,291 million and loss per share to JPY 49.19 from JPY 32.54.